Southwell Gavin, President and CEO, sold 7,647 shares of the Health Insurance Innovations, Inc. (NASDAQ:HIIQ) in an exchange that happened on April 5th. The stock was sold at an average price of $40.03 per share, amounting to a transaction worth $306,090. The purchase was made public in a document filed with the SEC. Additionally, Director FICHTHORN JOHN bought 90,742 shares of this stock in a transaction that took place on March 20th. The stock was bought at an average price of $29.27 per share, for a total exchange amounting to $2,655,664. After the transaction, the Director FICHTHORN JOHN currently holds 173,000 shares of the company’s stock, which is worth approximately $4126050.
With this stock price’s latest movement, it is now -62.22% away from its 1-year high and 10.16% higher than its 1-year low price. In the past seven days, the stock price volatility for Health Insurance Innovations, Inc. was 6.64%, whereas its volatility in the past 30 days has been 7.36%. This public company’s stock also has a beta score of 1.68. When the beta value is less/more than 1, it can imply that the stock is less/more volatile than the wider stock market – a metric that traders will surely be keeping tabs on.
Health Insurance Innovations, Inc. (NASDAQ:HIIQ) most recently published its quarterly earnings results. The firm posted $0.98 earnings per share (EPS) for the three-month period, surpassing analysts’ consensus estimate of $0.77 by $0.21. The publicly-traded organization reported revenue of $131.92 million for the quarter, compared to the average analyst forecast calling for $83.12 million, which was surpassing the analyst consensus estimate.
Shares of Health Insurance Innovations, Inc. (HIIQ) plunged -7.63%, amounting to a loss of -$1.97 per share, to finish the regular trading session at $23.85 on Friday April 12th, 2019. After beginning the session at $26.01, shares of Health Insurance Innovations, Inc. reached as high as $26.14 during the day, while hitting a 1-day low of $23.37. Trade volume reached 1,762,303 shares against this stock’s average daily volume of 957.83K shares, with a total float of 13.25M. As a consequence of the price decrease, Health Insurance Innovations, Inc. now has a current market value of 401.87M.
Takeda Pharmaceutical Company Limited (NYSE:TAK) subtracted -2.51% to its trading price by the close of the most recent session, dropping from its previous closing price of $19.53 to $19.04. This stock decreased in value by -5.27% during the last 7-day period, and experienced a loss of -8.59% over the past 30-day period. In the past three months, this stock’s price lost by -4.90% , and subtracted -3.59% to its price during the last six months of trading. TAK demonstrated a yearly price loss of -18.58% , while its year-to-date (YTD) price performance has been up 13.20% . This stock’s price changed by +0.32% compared to its 90-day low, and moved down -11.89% comparing to its 90-day high price.
Have a quick look on short, medium and long-term indicators. According to the Composite Indicator, Trendspotter rated the TAK stock as “Sell”. In the short-term, Takeda Pharmaceutical Company Limited (TAK) has a 20-day average volume of 2,022,275 shares and short-term indicators sets the TAK stock as “ 60% Sell ” on average basis. In the medium-term, TAK stock has a 50-Day average volume of 2,392,614 shares and medium-term indicators gave the average rating of “ 50% Sell ”, while in the long-term period the stock has a 100-Day average volume of 4,296,746 shares. On average, long-term indicators rated the stock as “33% Sell ”. The overall picture from all short, medium and long-term indicators sets the TAK stock as “56% Sell ” on average basis.
In other news related to Takeda Pharmaceutical Company Limited stock, Age shares of TAK held by institutions. The total number of institutions who held the TAK shares was 78, according to most recent SEC filling. During the past quarter, total 52 shares held by institutions with the net change of 53 shares. In the meantime, 60 new institutions bought the shares of Takeda Pharmaceutical Company Limited for the first time and 63 institutions sold all their holdings in the company’s common stock. 60 institutions increased their investment in the TAK stock and 62 institutions decreased their investment in the Takeda Pharmaceutical Company Limited (TAK)’s stock during the last quarter.